

DIALOGUES

I N C O N T R A C E P T I O N TM



Post-Test

The following Post-Test contains 10 multiple-choice questions based on information contained in the *Dialogues in Contraception*TM, Volume 8, Number 8, newsletter. It is designed to enable practitioners to assess the knowledge they have gained from the newsletter and to identify areas for further study.

On the Answer Sheet, fill in all identifying information requested. Complete the Answer Sheet by circling, in each case, the one response that most accurately answers the question.

1. What percentage of pregnant women have no prenatal care during the first trimester?
 - a. 10%
 - b. 20%
 - c. 30%
 - d. 40%
2. Which of the following is NOT a reason for discussing preconception care with all women of reproductive age?
 - a. unintended pregnancy can occur even during contraceptive use
 - b. intervention to minimize fetal risk must occur before conception
 - c. prenatal care may begin too late to reduce adverse pregnancy outcomes
 - d. only women planning pregnancy are likely to be interested in preconception care
3. Medications categorized as FDA category X teratogens include:
 - a. all nonsteroidal anti-inflammatory drugs
 - b. all antifungals
 - c. all thiazide diuretics
 - d. HMG-CoA reductase inhibitors
4. Folic acid supplementation prior to conception provides adequate stores of folate for an upcoming pregnancy and helps to reduce the incidence of:
 - a. anemia
 - b. vitamin B12 deficiency
 - c. neural tube defects (anencephaly, spina bifida)
 - d. cleft palate
5. The recommended amount of supplemental folic acid for women having had a prior pregnancy complicated with a neural tube defect is:
 - a. 1.0 mg/day
 - b. 4 mg/day
 - c. 5 mg/day
 - d. 14 mg/day
6. The single-rod etonogestrel implant is effective for ____ years.
 - a. 2
 - b. 3
 - c. 4
 - d. 5
7. Which of the following represent the mechanism(s) of action of implantable contraceptives?
 - a. positive feedback on the hypothalamic-pituitary axis
 - b. estrogen receptor binding
 - c. suppression of ovulation and inhibition of sperm penetration
 - d. abortifaction of implanted embryos
8. In clinical trials, the single-rod etonogestrel implant has demonstrated what level of contraceptive efficacy?
 - a. 70%
 - b. 80%
 - c. 90%
 - d. 100%
9. The adverse event rates reported with the etonogestrel implant, not including progestogenic side effects, are:
 - a. higher than those of earlier implants
 - b. comparable to women not using implants
 - c. minor, but thrombocytopenia is a concern
 - d. minimal except for adverse effects on bone density
10. Women using the etonogestrel implant:
 - a. ovulate normally throughout use
 - b. have persistent irregular bleeding
 - c. have an average 6% increase in body weight
 - d. experience a long delay in return to fertility

DIALOGUES

I N C O N T R A C E P T I O N TM



Post-Test Answer Sheet

- | | | | | | | | | | |
|----|---|---|---|---|-----|---|---|---|---|
| 1. | a | b | c | d | 6. | a | b | c | d |
| 2. | a | b | c | d | 7. | a | b | c | d |
| 3. | a | b | c | d | 8. | a | b | c | d |
| 4. | a | b | c | d | 9. | a | b | c | d |
| 5. | a | b | c | d | 10. | a | b | c | d |

CME or Nursing Contact Hour Enrollment

(PRINT)
NAME _____ DEGREE _____
FIRST LAST

MEDICAL LICENSE # _____ TELEPHONE NUMBER _____

ADDRESS _____

CITY _____ STATE _____ ZIP _____

SPECIALTY _____ E-MAIL _____

METHOD OF PAYMENT

- Check (payable to USC or NPWH)
 Credit Card

Visa/MasterCard # _____ Expiration Date _____

Authorized Signature _____ Amount \$ _____

To receive CME credit, please mail payment of \$15.00 or credit card information and this Answer Sheet to:

The Associate Dean, Office of Continuing Education, Keck School of Medicine of the University of Southern California
1975 Zonal Avenue, KAM 317, Los Angeles, CA 90033-1039
(323) 442-2555 or (800) USC-1119 – FAX (323) 442-2152 (for credit card payment only)

To receive nursing contact hours, please mail payment of \$15.00 or credit card information and this Answer Sheet to:

National Association of Nurse Practitioners in Women's Health
503 Capitol Court NE, Suite 300, Washington, DC 20002
(202) 543-9693 – FAX (202) 543-9858 (for credit card payment only)